Novavax (NVAX) Operating Leases (2020 - 2025)

Novavax's Operating Leases history runs 6 years deep, the most recent figure standing at $21.4 million for Q4 2025.

• In Q4 2025, Operating Leases fell 72.03% year-over-year to $21.4 million; the TTM figure through Dec 2025 stood at $21.4 million (down 72.03% YoY), while the FY2025 annual figure was $21.4 million, down 72.03% from the prior year.
• Operating Leases was $21.4 million for Q4 2025 at Novavax, down from $76.7 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $84.5 million in Q4 2023 to a low of $21.4 million in Q4 2025.
• Historically, Operating Leases has averaged $60.6 million across 5 years, with a median of $76.7 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Operating Leases soared 107.9% in 2022, then sank 72.03% in 2025.
• A 5-year view of Operating Leases shows it stood at $39.1 million in 2021, then jumped by 107.9% to $81.3 million in 2022, then climbed by 3.91% to $84.5 million in 2023, then fell by 9.25% to $76.7 million in 2024, then tumbled by 72.03% to $21.4 million in 2025.
• The last three Operating Leases figures came in at $21.4 million (Q4 2025), $76.7 million (Q4 2024), and $84.5 million (Q4 2023), per Business Quant data.